Everest Medicines Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 125.93 million compared to CNY 12.79 million a year ago. Net loss was CNY 844.46 million compared to CNY 247.28 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.05 HKD | +1.15% | -4.34% | +5.50% |
May. 14 | Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise | MT |
May. 14 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.50% | 903M | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- 1952 Stock
- News Everest Medicines Limited
- Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023